SEC Form 4 · accession 0001179110-19-000293
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Alpern
Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Equivalent UnitsF2,F1 | — | Dec 31, 2018 | A | 108 | A | — | — | Common shares | 108 | 7,270 | D |
Explanation of responses
- F1Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.
- F2Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.